Equity
€147,334 ▲ 0.2%
GUERRERO MED. paid out €68,193 in dividends. That is 100% of the 2025 profit.
GUERRERO MED.
Lifetime
13 annual accounts with figures on one time axispeak €110,154 (2025)
€110,154▲ 25.6%
peak €68,471 (2025)
€68,471▲ 26.4%
peak €147,334 (2025)
€147,334▲ 0.2%
€94,215▲ 132%
Board1 name since 2011
1 directorGUERRERO LOPEZ Cristina
Documentsfilings and deeds
24-02-202624 days late
2025micro format
Gross margin from €87,682 to €110,154Result from €54,190 to €68,471Dividend €68,193Debts from €40,544 to €94,215
Key points
from the 2025 annual accountsChecked score
95
Excellent
Financially stronger than 58% of micro companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 24,183 companies (NACE 86, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024
02-2025: < 0.1%● unchanged vs 01-2025highest value
03-2025: < 0.1%● unchanged vs 02-2025lowest value
04-2025: < 0.1%● unchanged vs 03-2025lowest value
05-2025: < 0.1%● unchanged vs 04-2025lowest value
06-2025: < 0.1%● unchanged vs 05-2025lowest value
07-2025: < 0.1%● unchanged vs 06-2025lowest value
08-2025: < 0.1%● unchanged vs 07-2025lowest value
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: < 0.1%● unchanged vs 07-2026
09-2026: < 0.1%● unchanged vs 08-2026
10-2026: < 0.1%● unchanged vs 09-2026
11-2026: < 0.1%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
lowers risk
Sector: Human health activities (NACE 86)
Liquidity: current ratio 2.41, cash €123,520
Size: total assets €241,550
Equity €147,334 (61.0% of total assets)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 49% of them on solvency, 64% on liquidity, 80% on profitability and 39% on growth.
The bankruptcy probability was computed on 07-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 30-06-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 34,693 companies had the same profile as GUERRERO MED. has now. Each dot stands for 87 companies, two years later.
95.3%
were still trading
3.9%
stopped another way
0.7%
went bankrupt
That fits the bankruptcy probability of GUERRERO MED. itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 34,693 companies, not a prediction for GUERRERO MED.. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €13,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 2.41 (3.96 in 2024), above the usual 1.5. Short-term debt is 39% and cash 51.1% of total assets. 39% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
5 signals, none raises the risk
Five signals.
lowers riskneutral
neutral · A punctual record breaks
This company filed 3 consecutive financial years on time. The year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 24-02-2026, 24 days late. Weigh it accordingly: of the companies that move to filing 1 to 90 days late, 1.41% are now bankrupt, dissolved or in another special legal status, below the 1.66% of all filers. It is a change in behaviour, not evidence of elevated risk.
NBB · 10 filingsDeviation from the deadline
2025
24 days late
2024
on the day
2023
on the day
2022
1 day early
2021
2 days late
2020
5 days early
2019
17 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average on the deadline day. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-06-2026 is due by 31-01-2027. Nothing is late today. The company usually files around 31 January (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
30-06-2026 year end08-11-2026 today31-01-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0844094889
Change of role: GUERRERO LOPEZ Cristina, from manager to director
Director discharge: GUERRERO LOPEZ Cristina · General meeting of 16-11-2023 · Gazette deed
Incorporation
published on 05-03-2012 · Gazette deed
First establishment
GUERRERO MED, Rue du Moulin 65, Gembloux
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| GUERRERO MED. Gembloux | €241,550 | €110,154 | 61.0% | - |
| DR. DELPORT ORTHO-EXPERT Waasmunster | €223,248 | €102,925 | 65.0% | - |
| Dr. Skröllan TACK, Dermatologie Rotselaar | €264,419 | €104,745 | 78.6% | 0 |
| Derm-AFL Woluwe-Saint-Lambert | €232,624 | €122,932 | 84.7% | - |
| Docteur Géraldine VANDENBOSSCHE Sprimont | €276,348 | €114,227 | 93.9% | - |
| DOCTEUR GENEVIEVE PIRSON Chaumont-Gistoux | €262,920 | €110,463 | 96.7% | - |
| DOKTER ELISE PANNIER ANESTHESIST Sint-Niklaas | €259,662 | €102,087 | 20.6% | - |
These companies have the same main activity as GUERRERO MED.: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €223,000 and €276,000, founded between 2010 and 2013.
Official details
Source: KBO- Status
- Active since 01-03-2012Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.251.686.0415030 Gembloux, since 01-03-2012
- Financial year end
- 30 June
- Peppol
- Reachable since 31-12-2025
Annual accounts to 30-06-2025
- ≈ €200,000estimated
- €241,550▲ 28.8%
- Filing
- Filed on 24-02-2026
Insights on GUERRERO MED.
GUERRERO MED. files the micro format. That format states no turnover. The gross margin rose from €91,932 in 2013 to €110,154 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about GUERRERO MED.
- What is the company number of GUERRERO MED.?
- The company number of GUERRERO MED. is 0844.094.889. The VAT number is the same number with BE in front: BE 0844.094.889.
- Where is GUERRERO MED. based?
- The registered office is at Rue du Moulin 65, 5030 Gembloux.Company details
- What does GUERRERO MED. do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of GUERRERO MED.?
- GUERRERO MED. is a private limited company (BV).
- When was GUERRERO MED. founded?
- GUERRERO MED. was founded on 01-03-2012.
- Is GUERRERO MED. still active?
- Yes, GUERRERO MED. is an active enterprise in the KBO register.
- What is the turnover of GUERRERO MED.?
- The turnover in financial year 2025 is ≈ €200,000. This figure is estimated from the gross margin of €110,154 and 41 comparable companies (NACE 86220). It probably lies between €170,000 and €270,000.Financials
- Is GUERRERO MED. profitable?
- In financial year 2025, GUERRERO MED. made a profit of €68,471.
- Where can I find the annual accounts of GUERRERO MED.?
- GUERRERO MED. filed 13 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of GUERRERO MED. due?
- GUERRERO MED. must file the annual accounts for financial year 2026 by 31-01-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.